



## Clinical trial results:

**Pilot Trial to preserve residual insulin secretion in children and adolescents with recent onset Type 1 diabetes by using GAD-antigen (Diamyd) therapy in combination with Vitamin D and Ibuprofen .**

### Summary

EudraCT number	2012-003251-11
Trial protocol	SE
Global end of trial date	30 November 2016

### Results information

Result version number	v1 (current)
This version publication date	14 June 2017
First version publication date	14 June 2017

### Trial information

#### Trial identification

Sponsor protocol code	DIABGAD-1
-----------------------	-----------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

### Sponsors

Sponsor organisation name	Div of Pediatrics, Dept of Clinical and Experimental Medicine, Faculty of Health Medicine
Sponsor organisation address	Linköping University, Linköping, Sweden, SE-581 85
Public contact	Johnny Ludvigsson, Linköping University, 46 13286854, Johnny.Ludvigsson@liu.se
Scientific contact	Johnny Ludvigsson, Linköping University, 46 13286854, Johnny.Ludvigsson@liu.se

Notes:

### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	30 November 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	30 November 2016
Global end of trial reached?	Yes
Global end of trial date	30 November 2016
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

- Evaluate the safety and influence of treatment with GAD-Alum (Diamyd) plus Vitamin D plus Ibuprofen on preservation of residual insulin secretion in recently-diagnosed Type 1 diabetes.
- Evaluate how the abovementioned treatments influence the immune system of the patients and interact with any viral infections.
- Evaluate the safety and influence of treatment with double dose of GAD-Alum (Diamyd) plus Vitamin D on the immune system, viral infections and on preservation of residual insulin secretion in recently-diagnosed Type 1 diabetes

Protection of trial subjects:

After the injection of GAD-Alum (Diamyd)/Placebo at Visit 3 and 4, the patient was to remain in the vicinity of the study site for the next hour, and the injection site were examined by investigator/study nurse 1 hour post injection.

Background therapy:

Standard insulin treatment, education and psycho-social support for newly diagnosed Type 1 diabetes patients. All patients will continue to receive standard care for Type 1 diabetes during the study.

Evidence for comparator: -

Actual start date of recruitment	04 February 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Sweden: 64
Worldwide total number of subjects	64
EEA total number of subjects	64

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23	0

months)	
Children (2-11 years)	17
Adolescents (12-17 years)	47
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

Patients were recruited from January 2013 to May 2014. Patients were recruited at 9 hospitals in Sweden.

### Pre-assignment

Screening details:

Patients aged 10.00 to 17.99 years at the time of screening and with Type 1 diabetes according to the ADA classification with < 4 months diabetes duration at time of screening.

### Period 1

Period 1 title	Baseline
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Group A

Arm description:

Patients will be assigned to receive Ibuprofen as oral suspension; 400 mg every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).

Arm type	Experimental
Investigational medicinal product name	D-vitamin Oil
Investigational medicinal product code	
Other name	Calciferol
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

Dosage and administration details:

The commercially available Vitamin D, calciferol. Vitamin D was administered as oral solution ; 2000 IU per day (i.e. 25 drops per day) from Day 1 through Day 450.

Investigational medicinal product name	Ibuprofen
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension
Routes of administration	Oral use

Dosage and administration details:

The commercially available ibuprofen.

Ibuprofen was administered as oral suspension; 400 mg every morning from Day 1 through 90.

<b>Arm title</b>	Group B
------------------	---------

Arm description:

Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	D-vitamin Oil
Investigational medicinal product code	
Other name	Calciferol
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

**Dosage and administration details:**

The commercially available Vitamin D, calciferol. Vitamin D was administered as oral solution ; 2000 IU per day (i.e. 25 drops per day) from Day 1 through Day 450.

Investigational medicinal product name	Placebo Ibuprofen
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension
Routes of administration	Oral use

**Dosage and administration details:**

Placebo ibuprofen was administered as oral suspension; every morning from Day 1 through 90.

<b>Arm title</b>	Group C
------------------	---------

**Arm description:**

Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 2 subcutaneous injections with 20 µg Diamyd given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster doses (providing a total dose of 80µg Diamyd).

Arm type	Experimental
Investigational medicinal product name	D-vitamin Oil
Investigational medicinal product code	
Other name	Calciferol
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

**Dosage and administration details:**

The commercially available Vitamin D, calciferol. Vitamin D was administered as oral solution ; 2000 IU per day (i.e. 25 drops per day) from Day 1 through Day 450.

Investigational medicinal product name	Placebo Ibuprofen
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension
Routes of administration	Oral use

**Dosage and administration details:**

Placebo ibuprofen was administered as oral suspension; every morning from Day 1 through 90.

<b>Arm title</b>	Group D
------------------	---------

**Arm description:**

Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and placebo oral drops from Day 1 through 450, and 2 subcutaneous injections with placebo (given at two different sites in the stomach area), each on Days 15 and 45

Arm type	Placebo
Investigational medicinal product name	Placebo D-vitamin Oil
Investigational medicinal product code	
Other name	Calciferol
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

**Dosage and administration details:**

Placebo was administered as oral solution i.e. 25 drops per day from Day 1 through Day 450.

Investigational medicinal product name	Placebo Ibuprofen
Investigational medicinal product code	
Other name	

Pharmaceutical forms	Oral suspension
Routes of administration	Oral use

Dosage and administration details:

Placebo ibuprofen was administered as oral suspension; every morning from Day 1 through 90.

Number of subjects in period 1	Group A	Group B	Group C
Started	16	16	16
Completed	16	16	16

Number of subjects in period 1	Group D
Started	16
Completed	16

## Period 2

Period 2 title	Baseline to Month 30
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Carer, Assessor

Blinding implementation details:

The treatment code was broken 24 March 2015, and data from Visit 1 to Visit 6 (6 months) were made available to one representative from the Sponsor (unblinded statistician), and the drug supplier (Diamyd Medical). The study was kept blinded to patients, investigators and study personnel until study completion.

## Arms

Are arms mutually exclusive?	Yes
Arm title	Group A

Arm description:

Patients will be assigned to receive Ibuprofen as oral suspension; 400 mg every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).

Arm type	Experimental
Investigational medicinal product name	D-vitamin Oil
Investigational medicinal product code	
Other name	Calciferol
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

Dosage and administration details:	
The commercially available Vitamin D, calciferol. Vitamin D was administered as oral solution ; 2000 IU per day (i.e. 25 drops per day) from Day 1 through Day 450.	
Investigational medicinal product name	Ibuprofen
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension
Routes of administration	Oral use
Dosage and administration details:	
The commercially available ibuprofen.	
Ibuprofen was administered as oral suspension; 400 mg every morning from Day 1 through 90.	
Investigational medicinal product name	Diamyd
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
1 x Diamyd injection.	
Diamyd 20 µg was administered as subcutaneous injections on Days 15 and 45 (prime and booster dose).	
The Diamyd® Drug Product was composed of the rhGAD65 protein formulated in a sterile, non-pyrogenic phosphate buffered saline containing the aluminum hydroxide adjuvant, Alhydrogel®.	
Diamyd® was administered as a 0.5 mL subcutaneous injection.	
Each injection contained 20 µg Diamyd® protein.	
Investigational medicinal product name	Placebo Diamyd
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use
Dosage and administration details:	
1 x Diamyd placebo injection containing 0 ug Diamyd.	
Diamyd placebo was administered as subcutaneous injections on Days 15 and 45 (prime and booster dose).	
A sterile, non-pyrogenic phosphate buffered saline containing the aluminum hydroxide adjuvant, Alhydrogel®. 0.5 mL subcutaneous injection.	
Arm title	Group B
Arm description:	
Patients will be assigned to receive placebo ibuprofen as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).	
Arm type	Experimental
Investigational medicinal product name	D-vitamin Oil
Investigational medicinal product code	
Other name	Calciferol
Pharmaceutical forms	Oral solution
Routes of administration	Oral use
Dosage and administration details:	
The commercially available Vitamin D, calciferol. Vitamin D was administered as oral solution ; 2000 IU per day (i.e. 25 drops per day) from Day 1 through Day 450.	
Investigational medicinal product name	Placebo Ibuprofen
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension
Routes of administration	Oral use

Dosage and administration details:	
Placebo ibuprofen was administered as oral suspension; every morning from Day 1 through 90.	
Investigational medicinal product name	Diamyd
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

1 x Diamyd injection.

Diamyd 20 µg was administered as subcutaneous injections on Days 15 and 45 (prime and booster dose).

The Diamyd® Drug Product was composed of the rhGAD65 protein formulated in a sterile, non-pyrogenic phosphate buffered saline containing the aluminum hydroxide adjuvant, Alhydrogel®.

Diamyd® was administered as a 0.5 mL subcutaneous injection.

Each injection contained 20 µg Diamyd® protein.

Investigational medicinal product name	Placebo Diamyd
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

1 x Diamyd placebo injection containing 0 ug Diamyd.

Diamyd placebo was administered as subcutaneous injections on Days 15 and 45 (prime and booster dose).

A sterile, non-pyrogenic phosphate buffered saline containing the aluminum hydroxide adjuvant, Alhydrogel®. 0.5 mL subcutaneous injection.

<b>Arm title</b>	Group C
------------------	---------

Arm description:

Patients will be assigned to receive placebo ibuprofen as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 2 subcutaneous injections with 20 µg Diamyd given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster doses (providing a total dose of 80µg Diamyd).

Arm type	Experimental
Investigational medicinal product name	Placebo Ibuprofen
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension
Routes of administration	Oral use

Dosage and administration details:

Placebo ibuprofen was administered as oral suspension; every morning from Day 1 through 90.

Investigational medicinal product name	D-vitamin Oil
Investigational medicinal product code	
Other name	Calciferol
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

Dosage and administration details:

The commercially available Vitamin D, calciferol. Vitamin D was administered as oral solution ; 2000 IU per day (i.e. 25 drops per day) from Day 1 through Day 450.

Investigational medicinal product name	Diamyd
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

1 x Diamyd injection.



Diamyd 20 µg was administered as subcutaneous injections, on Days 15 and 45 (prime and booster dose).

The Diamyd® Drug Product was composed of the rhGAD65 protein formulated in a sterile, non-pyrogenic phosphate buffered saline containing the aluminum hydroxide adjuvant, Alhydrogel®.

Diamyd® was administered as a 0.5 mL subcutaneous injection.

Each injection contained 20 µg Diamyd® protein.

Investigational medicinal product name	Diamyd
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Suspension for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

1 x Diamyd injection.

Diamyd 20 µg was administered as subcutaneous injections on Days 15 and 45 (prime and booster dose).

The Diamyd® Drug Product was composed of the rhGAD65 protein formulated in a sterile, non-pyrogenic phosphate buffered saline containing the aluminum hydroxide adjuvant, Alhydrogel®.

Diamyd® was administered as a 0.5 mL subcutaneous injection.

Each injection contained 20 µg Diamyd® protein.

<b>Arm title</b>	Group D
------------------	---------

Arm description:

Patients will be assigned to receive placebo ibuprofen as oral suspension every morning from Day 1 through 90 and placebo oral drops from Day 1 through 450, and 2 subcutaneous injections with placebo (given at two different sites in the stomach area), each on Days 15 and 45

Arm type	Placebo
Investigational medicinal product name	Placebo Ibuprofen
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension
Routes of administration	Oral use

Dosage and administration details:

Placebo ibuprofen was administered as oral suspension; every morning from Day 1 through 90.

Investigational medicinal product name	Placebo D-vitamin Oil
Investigational medicinal product code	
Other name	Calciferol
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

Dosage and administration details:

Placebo was administered as oral solution i.e. 25 drops per day from Day 1 through Day 450.

Investigational medicinal product name	Placebo Diamyd
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

1 x Diamyd placebo injection containing 0 ug Diamyd.

Diamyd placebo was administered as subcutaneous injections on Days 15 and 45 (prime and booster dose).

A sterile, non-pyrogenic phosphate buffered saline containing the aluminum hydroxide adjuvant, Alhydrogel®. 0.5 mL subcutaneous injection.

Investigational medicinal product name	Placebo Diamyd
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

---

**Dosage and administration details:**

1 x Diamyd placebo injection containing 0 ug Diamyd.

Diamyd placebo was administered as subcutaneous injections on Days 15 and 45 (prime and booster dose).

A sterile, non-pyrogenic phosphate buffered saline containing the aluminum hydroxide adjuvant, Alhydrogel®. 0.5 mL subcutaneous injection.

<b>Number of subjects in period 2<sup>[1]</sup></b>	Group A	Group B	Group C
Started	16	16	16
Prime injection Diamyd/Placebo	16	16	16
Boost injection Diamyd/Placebo	16	16	15
Completed 6 month visit	16	16	15
Completed 15 month visit	15	16	15
Completed 30 month visit	15	16	15
Completed	15	16	15
Not completed	1	0	1
Consent withdrawn by subject	1	-	1
Physician decision	-	-	-

<b>Number of subjects in period 2<sup>[1]</sup></b>	Group D
Started	15
Prime injection Diamyd/Placebo	15
Boost injection Diamyd/Placebo	15
Completed 6 month visit	13
Completed 15 month visit	13
Completed 30 month visit	13
Completed	13
Not completed	2
Consent withdrawn by subject	1
Physician decision	1

---

**Notes:**

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: 1 patient in Group D completed Baseline but decided not to continue in the study after baseline visit.

## Baseline characteristics

### Reporting groups

Reporting group title	Group A
Reporting group description:	
Patients will be assigned to receive Ibuprofen as oral suspension; 400 mg every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).	
Reporting group title	Group B
Reporting group description:	
Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).	
Reporting group title	Group C
Reporting group description:	
Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 2 subcutaneous injections with 20 µg Diamyd given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster doses (providing a total dose of 80µg Diamyd).	
Reporting group title	Group D
Reporting group description:	
Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and placebo oral drops from Day 1 through 450, and 2 subcutaneous injections with placebo (given at two different sites in the stomach area), each on Days 15 and 45	

Reporting group values	Group A	Group B	Group C
Number of subjects	16	16	16
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	5	4	6
Adolescents (12-17 years)	11	12	10
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
arithmetic mean	13.3	14.4	13.3
standard deviation	± 1.9	± 2.7	± 2.4
Gender categorical			
Units: Subjects			
Female	6	7	10
Male	10	9	6

<b>Reporting group values</b>	Group D	Total	
Number of subjects	16	64	
Age categorical Units: Subjects			
In utero	0	0	
Preterm newborn infants (gestational age < 37 wks)	0	0	
Newborns (0-27 days)	0	0	
Infants and toddlers (28 days-23 months)	0	0	
Children (2-11 years)	2	17	
Adolescents (12-17 years)	14	47	
Adults (18-64 years)	0	0	
From 65-84 years	0	0	
85 years and over	0	0	
Age continuous Units: years			
arithmetic mean	14.2		
standard deviation	± 2.2	-	
Gender categorical Units: Subjects			
Female	9	32	
Male	7	32	

## End points

### End points reporting groups

Reporting group title	Group A
Reporting group description: Patients will be assigned to receive Ibuprofen as oral suspension; 400 mg every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).	
Reporting group title	Group B
Reporting group description: Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).	
Reporting group title	Group C
Reporting group description: Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 2 subcutaneous injections with 20 µg Diamyd given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster doses (providing a total dose of 80µg Diamyd).	
Reporting group title	Group D
Reporting group description: Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and placebo oral drops from Day 1 through 450, and 2 subcutaneous injections with placebo (given at two different sites in the stomach area), each on Days 15 and 45	
Reporting group title	Group A
Reporting group description: Patients will be assigned to receive Ibuprofen as oral suspension; 400 mg every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).	
Reporting group title	Group B
Reporting group description: Patients will be assigned to receive placebo ibuprofen as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).	
Reporting group title	Group C
Reporting group description: Patients will be assigned to receive placebo ibuprofen as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 2 subcutaneous injections with 20 µg Diamyd given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster doses (providing a total dose of 80µg Diamyd).	
Reporting group title	Group D
Reporting group description: Patients will be assigned to receive placebo ibuprofen as oral suspension every morning from Day 1 through 90 and placebo oral drops from Day 1 through 450, and 2 subcutaneous injections with placebo (given at two different sites in the stomach area), each on Days 15 and 45	

**Primary: Change in AUC for C-peptide from baseline to month 6**

End point title	Change in AUC for C-peptide from baseline to month 6 <sup>[1]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From baseline to 6 months

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The clinical study protocol defined statistical methods for efficacy data regarding C-peptide and immune system as well as Adverse events and other safety data as being composed of summary tables with descriptive statistics.

End point values	Group A	Group B	Group C	Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	15	14	10
Units: AUC for C-peptide (nmol/L				
arithmetic mean (standard deviation)	-0.264 (± 0.231)	-0.114 (± 0.164)	-0.19 (± 0.161)	0.008 (± 0.271)

**Statistical analyses**

No statistical analyses for this end point

**Primary: Change in AUC for C-peptide from baseline to month 15**

End point title	Change in AUC for C-peptide from baseline to month 15 <sup>[2]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

From baseline to Month 15

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The clinical study protocol defined statistical methods for efficacy data regarding C-peptide and immune system as well as Adverse events and other safety data as being composed of summary tables with descriptive statistics.

End point values	Group A	Group B	Group C	Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	15	14	10
Units: AUC for C-peptide (nmol/L)				
arithmetic mean (standard deviation)	-0.362 (± 0.243)	-0.195 (± 0.167)	-0.277 (± 0.216)	-0.273 (± 0.245)

**Statistical analyses**

No statistical analyses for this end point

---

**Primary: Change in AUC for C-peptide from baseline to month 30**

---

End point title	Change in AUC for C-peptide from baseline to month 30 <sup>[3]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Baseline to Month 30

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The clinical study protocol defined statistical methods for efficacy data regarding C-peptide and immune system as well as Adverse events and other safety data as being composed of summary tables with descriptive statistics.

End point values	Group A	Group B	Group C	Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	14	14	11
Units: AUC for C-peptide (nmol/L)				
arithmetic mean (standard deviation)	-0.512 (± 0.318)	-0.383 (± 0.161)	-0.458 (± 0.209)	-0.405 (± 0.257)

---

**Statistical analyses**

---

No statistical analyses for this end point

---

**Primary: Change in mean fasting C-peptide, baseline to month 6**

---

End point title	Change in mean fasting C-peptide, baseline to month 6 <sup>[4]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Baseline to Visit 6

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The clinical study protocol defined statistical methods for efficacy data regarding C-peptide and immune system as well as Adverse events and other safety data as being composed of summary tables with descriptive statistics.

End point values	Group A	Group B	Group C	Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	15	14	10
Units: Mean fasting C-peptide (nmol/L)				
arithmetic mean (standard deviation)	-0.108 (± 0.195)	-0.015 (± 0.143)	-0.068 (± 0.133)	0.023 (± 0.191)

## Statistical analyses

No statistical analyses for this end point

### Primary: Change in mean fasting C-peptide, baseline to month 15

End point title	Change in mean fasting C-peptide, baseline to month 15 <sup>[5]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Baseline to month 15

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The clinical study protocol defined statistical methods for efficacy data regarding C-peptide and immune system as well as Adverse events and other safety data as being composed of summary tables with descriptive statistics.

End point values	Group A	Group B	Group C	Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	15	14	10
Units: Mean fasting C-peptide (nmol/L)				
arithmetic mean (standard deviation)	-0.131 (± 0.166)	-0.061 (± 0.143)	-0.142 (± 0.133)	-0.039 (± 0.185)

## Statistical analyses

No statistical analyses for this end point

### Primary: Change in mean fasting C-peptide, baseline to month 30

End point title	Change in mean fasting C-peptide, baseline to month 30 <sup>[6]</sup>
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Baseline to month 30

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The clinical study protocol defined statistical methods for efficacy data regarding C-peptide and immune system as well as Adverse events and other safety data as being composed of summary tables with descriptive statistics.

End point values	Group A	Group B	Group C	Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	14	14	11
Units: Mean fasting C-peptide (nmol/L)				
arithmetic mean (standard deviation)	-0.194 (± 0.204)	-0.134 (± 0.133)	-0.203 (± 0.124)	-0.13 (± 0.117)



## Statistical analyses

No statistical analyses for this end point

### Primary: Change in HbA1c from baseline to month 15

End point title	Change in HbA1c from baseline to month 15 <sup>[7]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Baseline to 15 Months

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The clinical study protocol defined statistical methods for efficacy data regarding C-peptide and immune system as well as Adverse events and other safety data as being composed of summary tables with descriptive statistics.

End point values	Group A	Group B	Group C	Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	11	15	14	10
Units: HbA1c (mmol/mol)				
arithmetic mean (standard deviation)	5.455 (± 7.751)	5.667 (± 15.407)	5.643 (± 9.951)	6.5 (± 10.967)

## Statistical analyses

No statistical analyses for this end point

### Primary: Change in HbA1c from baseline to month 30

End point title	Change in HbA1c from baseline to month 30 <sup>[8]</sup>
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Baseline to Month 30.

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The clinical study protocol defined statistical methods for efficacy data regarding C-peptide and immune system as well as Adverse events and other safety data as being composed of summary tables with descriptive statistics.

<b>End point values</b>	Group A	Group B	Group C	Group D
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	14	14	11
Units: HbA1c (mmol/mol)				
arithmetic mean (standard deviation)	12.4 (± 5.816)	13.286 (± 15.563)	7.286 (± 11.323)	10.909 (± 16.837)

## Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse Events were recorded by the physician at every visit throughout the study.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	20
--------------------	----

### Reporting groups

Reporting group title	Group A
-----------------------	---------

Reporting group description:

Patients will be assigned to receive Ibuprofen as oral suspension; 400 mg every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).

Reporting group title	Group B
-----------------------	---------

Reporting group description:

Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 1 subcutaneous injection with 20 µg Diamyd and one with placebo given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster dose (providing a total dose of 40 µg Diamyd).

Reporting group title	Group C
-----------------------	---------

Reporting group description:

Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and from Day 1 through 450 also oral drops of Vitamin D 2000 IU per day (i.e. 25 drops per day). In addition 2 subcutaneous injections with 20 µg Diamyd given at two different sites in the stomach area, each on Days 15 and 45, i.e., prime and booster doses (providing a total dose of 80µg Diamyd).

Reporting group title	Group D
-----------------------	---------

Reporting group description:

Patients will be assigned to receive placebo as oral suspension every morning from Day 1 through 90 and placebo oral drops from Day 1 through 450, and 2 subcutaneous injections with placebo (given at two different sites in the stomach area), each on Days 15 and 45

Serious adverse events	Group A	Group B	Group C
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 16 (0.00%)	3 / 16 (18.75%)	2 / 16 (12.50%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Injury, poisoning and procedural complications			
Upper limb fracture			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			

Abdominal pain			
subjects affected / exposed	0 / 16 (0.00%)	1 / 16 (6.25%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 16 (0.00%)	1 / 16 (6.25%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastroenteritis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 16 (0.00%)	1 / 16 (6.25%)	0 / 16 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

<b>Serious adverse events</b>	Group D		
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 15 (13.33%)		
number of deaths (all causes)	0		
number of deaths resulting from adverse events	0		
Injury, poisoning and procedural complications			
Upper limb fracture			

subjects affected / exposed	1 / 15 (6.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Appendicitis			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastroenteritis			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 1 %

<b>Non-serious adverse events</b>	Group A	Group B	Group C
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 16 (75.00%)	15 / 16 (93.75%)	16 / 16 (100.00%)
Surgical and medical procedures			
Breast operation			
subjects affected / exposed	0 / 16 (0.00%)	1 / 16 (6.25%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Injection site oedema			
subjects affected / exposed	0 / 16 (0.00%)	1 / 16 (6.25%)	1 / 16 (6.25%)
occurrences (all)	0	2	1
Injection site rash			
subjects affected / exposed	1 / 16 (6.25%)	1 / 16 (6.25%)	0 / 16 (0.00%)
occurrences (all)	1	2	0
Injection site reaction			
subjects affected / exposed	5 / 16 (31.25%)	4 / 16 (25.00%)	6 / 16 (37.50%)
occurrences (all)	8	5	7
Pyrexia			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	2
Injection site pain			
subjects affected / exposed	0 / 16 (0.00%)	2 / 16 (12.50%)	1 / 16 (6.25%)
occurrences (all)	0	3	1
Injection site nodule			
subjects affected / exposed	2 / 16 (12.50%)	1 / 16 (6.25%)	2 / 16 (12.50%)
occurrences (all)	2	1	2
Injection site erythema			
subjects affected / exposed	1 / 16 (6.25%)	1 / 16 (6.25%)	3 / 16 (18.75%)
occurrences (all)	1	1	3
Injection site swelling			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	2
Injection site haematoma			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Peripheral swelling			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Fatigue subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	1 / 16 (6.25%) 2
Respiratory, thoracic and mediastinal disorders			
Epistaxis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1
Psychiatric disorders			
Depression subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0
Obsessive-compulsive disorder subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Attention deficit/hyperactivity disorder subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0
Investigations			
Blood cholesterol increased subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1
Injury, poisoning and procedural complications			
Back injury subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0
Road traffic accident			

subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0
Dermatitis contact subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Ligament sprain subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0
Juvenile myoclonic epilepsy subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Blood and lymphatic system disorders Anaemia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Gastrointestinal disorders Nausea subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0
Abdominal pain			



subjects affected / exposed	0 / 16 (0.00%)	1 / 16 (6.25%)	0 / 16 (0.00%)
occurrences (all)	0	2	0
Abdominal pain upper			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Gastritis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Coeliac disease			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Toothache			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Skin and subcutaneous tissue disorders			
Urticaria			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Pruritus genital			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Rash			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0

Acne subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Renal and urinary disorders Microalbuminuria subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1
Endocrine disorders Hyperthyroidism subjects affected / exposed occurrences (all)  Hypothyroidism subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0  0 / 16 (0.00%) 0	0 / 16 (0.00%) 0  0 / 16 (0.00%) 0	1 / 16 (6.25%) 1  0 / 16 (0.00%) 0
Musculoskeletal and connective tissue disorders Muscle twitching subjects affected / exposed occurrences (all)  Costochondritis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0  0 / 16 (0.00%) 0	0 / 16 (0.00%) 0  0 / 16 (0.00%) 0	1 / 16 (6.25%) 1  0 / 16 (0.00%) 0
Infections and infestations Viral infection subjects affected / exposed occurrences (all)  Ear infection subjects affected / exposed occurrences (all)  Pharyngitis subjects affected / exposed occurrences (all)  Upper respiratory tract infection subjects affected / exposed occurrences (all)  Urinary tract infection	1 / 16 (6.25%) 1  1 / 16 (6.25%) 2  1 / 16 (6.25%) 1  0 / 16 (0.00%) 0	2 / 16 (12.50%) 2  0 / 16 (0.00%) 0  0 / 16 (0.00%) 0  1 / 16 (6.25%) 3	1 / 16 (6.25%) 1  0 / 16 (0.00%) 0  0 / 16 (0.00%) 0  0 / 16 (0.00%) 0

subjects affected / exposed	0 / 16 (0.00%)	1 / 16 (6.25%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	6 / 16 (37.50%)	7 / 16 (43.75%)	7 / 16 (43.75%)
occurrences (all)	10	8	8
Tonsillitis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 16 (6.25%)	1 / 16 (6.25%)
occurrences (all)	0	1	1
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Pseudocroup			
subjects affected / exposed	1 / 16 (6.25%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis			
subjects affected / exposed	1 / 16 (6.25%)	2 / 16 (12.50%)	1 / 16 (6.25%)
occurrences (all)	1	3	1
Tinea infection			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	1 / 16 (6.25%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Cystitis			
subjects affected / exposed	0 / 16 (0.00%)	1 / 16 (6.25%)	0 / 16 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	1 / 16 (6.25%)	0 / 16 (0.00%)	0 / 16 (0.00%)
occurrences (all)	1	0	0
Varicella			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	1 / 16 (6.25%)
occurrences (all)	0	0	1
Rhinitis			
subjects affected / exposed	0 / 16 (0.00%)	0 / 16 (0.00%)	2 / 16 (12.50%)
occurrences (all)	0	0	2
Borrelia infection			

subjects affected / exposed occurrences (all)	1 / 16 (6.25%) 1	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0
Infectious mononucleosis subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1
Metabolism and nutrition disorders Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 16 (0.00%) 0	0 / 16 (0.00%) 0	1 / 16 (6.25%) 1

<b>Non-serious adverse events</b>	Group D		
Total subjects affected by non-serious adverse events subjects affected / exposed	14 / 15 (93.33%)		
Surgical and medical procedures Breast operation subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0		
General disorders and administration site conditions Injection site oedema subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1		
Injection site rash subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0		
Injection site reaction subjects affected / exposed occurrences (all)	6 / 15 (40.00%) 7		
Pyrexia subjects affected / exposed occurrences (all)	2 / 15 (13.33%) 2		
Injection site pain subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0		
Injection site nodule subjects affected / exposed occurrences (all)	2 / 15 (13.33%) 3		
Injection site erythema			

subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Injection site swelling			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Injection site haematoma			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Peripheral swelling			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Respiratory, thoracic and mediastinal disorders			
Epistaxis			
subjects affected / exposed	2 / 15 (13.33%)		
occurrences (all)	2		
Oropharyngeal pain			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Psychiatric disorders			
Depression			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	1		
Obsessive-compulsive disorder			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	1		
Attention deficit/hyperactivity disorder			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Investigations			
Blood cholesterol increased			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Haemoglobin decreased			

subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0		
Injury, poisoning and procedural complications			
Back injury			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Road traffic accident			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	1		
Fall			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Dermatitis contact			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	2		
Ligament sprain			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	1		
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	2		
Juvenile myoclonic epilepsy			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Blood and lymphatic system disorders			

Anaemia subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1		
Gastrointestinal disorders			
Nausea subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1		
Abdominal pain subjects affected / exposed occurrences (all)	2 / 15 (13.33%) 2		
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0		
Gastritis subjects affected / exposed occurrences (all)	2 / 15 (13.33%) 2		
Diarrhoea subjects affected / exposed occurrences (all)	2 / 15 (13.33%) 2		
Coeliac disease subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0		
Toothache subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1		
Vomiting subjects affected / exposed occurrences (all)	0 / 15 (0.00%) 0		
Skin and subcutaneous tissue disorders			
Urticaria subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1		
Pruritus genital subjects affected / exposed occurrences (all)	1 / 15 (6.67%) 1		
Rash papular			

<p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Eczema</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Rash</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Acne</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 15 (6.67%)</p> <p>1</p> <p>0 / 15 (0.00%)</p> <p>0</p> <p>1 / 15 (6.67%)</p> <p>1</p> <p>1 / 15 (6.67%)</p> <p>1</p>		
<p>Renal and urinary disorders</p> <p>Microalbuminuria</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 15 (0.00%)</p> <p>0</p>		
<p>Endocrine disorders</p> <p>Hyperthyroidism</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hypothyroidism</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 15 (0.00%)</p> <p>0</p> <p>1 / 15 (6.67%)</p> <p>1</p>		
<p>Musculoskeletal and connective tissue disorders</p> <p>Muscle twitching</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Costochondritis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 15 (0.00%)</p> <p>0</p> <p>1 / 15 (6.67%)</p> <p>1</p>		
<p>Infections and infestations</p> <p>Viral infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Ear infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 15 (0.00%)</p> <p>0</p> <p>0 / 15 (0.00%)</p> <p>0</p>		



Pharyngitis			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	3 / 15 (20.00%)		
occurrences (all)	4		
Urinary tract infection			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	4 / 15 (26.67%)		
occurrences (all)	4		
Tonsillitis			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	1		
Viral upper respiratory tract infection			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Pseudocroup			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Gastroenteritis			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	1		
Tinea infection			
subjects affected / exposed	1 / 15 (6.67%)		
occurrences (all)	1		
Influenza			
subjects affected / exposed	3 / 15 (20.00%)		
occurrences (all)	3		
Cystitis			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		

Varicella			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Rhinitis			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Borrelia infection			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Infectious mononucleosis			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Hypoglycaemia			
subjects affected / exposed	0 / 15 (0.00%)		
occurrences (all)	0		

## **More information**

### **Substantial protocol amendments (globally)**

Were there any global substantial amendments to the protocol? No

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

None reported